PER® Miami Breast Cancer Conference | Conference

Dr. Hurvitz on FDA Approval of Subcutaneous Trastuzumab Formulation in HER2+ Breast Cancer

March 9th 2019

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the recent FDA approval of subcutaneous use of trastuzumab (Herceptin) and hyaluronidase-oysk injection (Herceptin Hylecta) in the HER2-positive breast cancer space.

Getting It Right in Breast Cancer Means Being More Precise

March 8th 2019

After nearly 30 years as a breast cancer surgeon, Patrick I. Borgen, MD, finds that the most enduring theme in the field is constant change.

Top Developments in Breast Cancer Research Shape the MBCC Agenda

March 8th 2019

The breast cancer field is experiencing rapid advancements in the understanding of disease biology and the development of novel therapeutic strategies for several subtypes, with a clear direction toward personalized or precision medicine.

Intraoperative Shave Technique Proves Effective in Breast-Conserving Surgery

March 8th 2019

Data from the SHAVE and SHAVE2 trials, in terms of long-term outcomes vis-à-vis local recurrence, may lend some insight into the impact of adjuvant therapy on reducing the ramifications of a positive margin.

Managing Cardiac AEs in HER2-Positive Breast Cancer

March 16th 2018

Jean-Bernard Durand, MD, discusses the possibility of repairing cardiac damage in patients with HER2-positive breast cancer.

Preventing Clinical Lymphedema With Bioimpedance Spectroscopy

March 14th 2018

Employing preclinical detection using bioimpedance spectroscopy, breast centers are reporting progression to clinical lymphedema in less than 10% of patients at high risk of developing the condition.

Hospitalists and Nonphysician Providers Can Step Into the Breach

March 14th 2018

Andrew Seidman, MD, focuses on his view of the increasing role of nurse practitioners in the outpatient setting and hospitalists in the inpatient setting.

Looking for a Therapeutic Edge Among CDK Inhibitors

March 13th 2018

Whenever 3 agents joining the therapeutic armamentarium do so for similar indications with essentially identical mechanisms of action, it is reasonable to ask whether these agents have specific differences that might help decide which to use.

Testing the Power of Neoadjuvant Systemic Therapy in Breast Cancer

March 13th 2018

Neoadjuvant therapy can eliminate both invasive and in situ carcinoma in up to 50% of patients, particularly when their subtypes are triple-negative disease or HER2-positive cancers.

Abemaciclib Data Reviewed as New Breast Cancer Indications Added

March 12th 2018

Abemaciclib (Verzenio) has quickly amassed several clinical indications for patients with metastatic breast cancer, and is the only CDK4/6 inhibitor approved as a single agent.

Dr. Borgen on the Evolution of Breast Cancer Treatment

March 11th 2018

Patrick I. Borgen, MD, chairman of surgery, director of the Breast Cancer Program, Maimonides Medical Center, and chair of the Miami Breast Cancer Conference, discusses the evolution of breast cancer treatment in recent years. Borgen shared his insight in an interview during the meeting.

Dr. Hurvitz on Novel Emerging Agents in HER2+ Breast Cancer

March 11th 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program at the University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses novel agents that are emerging in the HER2-positive breast cancer space. Hurvitz shared this insight in an interview with OncLive during the 35th Annual Miami Breast Cancer Conference.

Neoadjuvant Endocrine Therapy Ideal for Some Breast Cancer Patients

March 11th 2018

Endocrine therapy can achieve tumor reduction for patients with ER-positive breast cancer, possibly avoiding the need for chemotherapy or even surgery in some patients; however, deciding how long to continue this therapy can be tricky.

AJCC Staging Manual Gives Boost to Precision Medicine

March 11th 2018

The latest revision of the staging manual for breast cancer from the American Joint Committee on Cancer is a quantum leap toward precision oncology, as it codifies advanced knowledge of the role of biologic factors in cancer, and oncologists should now be using it.

PARP Inhibitors Arrive for BRCA+ Breast Cancer

March 11th 2018

The PARP inhibitors have finally become available for patients with BRCA-mutant metastatic breast cancer, ushering in a potential new era for targeted therapies with studies currently ongoing in the adjuvant setting and exploring combinations.

Dual Targeting Advances in HER2+/HR+ Breast Cancer

March 11th 2018

The discovery of crosstalk between the HER2 and hormone receptor pathways has led to the promising treatment strategy of dual targeting regimens.

Hurvitz Heralds Next HER2+ Breast Cancer Breakthroughs

March 10th 2018

Several new agents have emerged in HER2-positive breast cancer with the potential to further alter the natural course of the disease.

Dr. Robson on Exploratory Analysis From OlympiAD in Breast Cancer

March 9th 2018

Mark E. Robson, MD, chief, Breast Medicine Service, Memorial Sloan Kettering Cancer Center, discusses an exploratory analysis of the OlympiAD trial for patients with HER2-negative breast cancer with a germline BRCA1/2 mutation.

Frontline Palbociclib Effective Regardless of Prior Treatment in Breast Cancer Subgroups

March 9th 2018

Palbociclib (Ibrance) demonstrated significant efficacy in combination with letrozole (Femara) in the frontline setting of estrogen receptor-positive, HER2-negative, postmenopausal metastatic breast cancer.

Dr. Andre on Questions With Immunotherapy in Triple-Negative Breast Cancer

March 9th 2018

Fabrice André, MD, professor, Department of Medical Oncology, Institut Gustave Roussy, discusses the remaining questions with immunotherapy agents as potential therapy for patients with triple-negative breast cancer. Andre expanded on this in an interview with OncLive during the 35th Annual Miami Breast Cancer Conference.